Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
QRxPharma logo — Pioneering pain management with innovative products and adva...

QRxPharma

Pioneering pain management with innovative products and advanced abuse prevention technologies

Founded 2002 Post-IPO Equity Total: $34.50M Biopharma, Biotechnology +1

General Information

Company Name QRxPharma
Founded Year 2002
Founders / Decision Makers
Team member Team member
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with QRxPharma. To contact QRxPharma, visit qrxpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does QRxPharma compare?

A PDF of QRxPharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting QRxPharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About QRxPharma

QRxPharma is an Australian specialty pharmaceutical company focused on developing and commercializing innovative pain management and abuse prevention products. The company's portfolio includes both late and early-stage clinical drug candidates, designed to offer reduced risk, shorter development timelines, and improved patient outcomes. In Q4 2013, QRxPharma plans to resubmit a New Drug Application with the US Food and Drug Administration for its main product, immediate release MOXDUO®, aimed at treating acute pain. The company has secured strategic partnerships with Actavis Inc., Paladin Labs Inc., and Aspen Group for the commercialization of immediate release MOXDUO in the United States, Canada, Australia, and South Africa. Additionally, QRxPharma is working on intravenous (IV) and controlled-release (CR) formulations of MOXDUO, as well as with Aesica Formulation Development Limited to promote its proprietary Stealth Beadlets™ abuse deterrent technology on a global scale. The company received a $11.60M investment in post-IPO equity at 13 December 2013. Overall, QRxPharma is pioneering pain management and abuse prevention in the biopharma, biotechnology, and healthcare industries.

Business keywords: pharmaceutical company, pain management, drug development, clinical pipeline, New Drug Application, FDA approval, strategic partnerships, abuse prevention technology, specialty pharmaceuticals, acute pain treatment, commercialization, innovative products, clinical drug candidates, global scale collaborations, Australian-based company

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $11.60M -
13 Dec 2013
Post IPO Debt $12.40M -
30 Dec 2009
Series A $500.00K 1
Plymouth Growth
Plymouth Growth
30 Apr 2003
Series A $10.00M 4
Uniseed Innovation Capital Nanyang Ventures
Uniseed, Innovation Capital +2
10 Dec 2002

QRxPharma Alternatives & Competitors

View All Alternatives
QRxPharma vs
Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals United States

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company w...

Venture round
50 employees
Biotechnology, Health Care
QRxPharma vs
SFJ Pharmaceuticals, Inc.
SFJ Pharmaceuticals, Inc. United States

SFJ Pharmaceuticals® is a global specialty pharmaceutical company with an innovative pharmaceutical...

Venture round
30 employees
Biotechnology, Health Care
QRxPharma vs
Replidyne
Replidyne

Developing groundbreaking anti-infective products through proprietary DNA replication technology and...

Series A
Biopharma, Biotechnology
View all alternatives

FAQ About QRxPharma

Pioneering pain management with innovative products and advanced abuse prevention technologies
QRxPharma was founded in 2002.
QRxPharma operates in Biopharma, Biotechnology and Health Care. Its work centres on pharmaceutical company, pain management, drug development and clinical pipeline.
QRxPharma has completed 4 funding rounds, raising a total of $34.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to QRxPharma include Xanodyne Pharmaceuticals, SFJ Pharmaceuticals, Inc., Replidyne, Veloxis Pharmaceuticals, Inc., XSPRAY PHARMA AB (PUBL). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
QRxPharma and Xanodyne Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for QRxPharma, https://bouncewatch.com/company/qrxpharma, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes